3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
175
Recurrence
32
Neoplasms, Plasma Cell
16
Lymphoma
11
Waldenstrom Macroglobulinemia
6
Neoplasms
6
Lymphoma, Mantle-Cell
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
5
Smoldering Multiple Myeloma
4
Leukemia
4
Small Cell Lung Carcinoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Plasma Cell
3
Hodgkin Disease
3
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Disease
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Sezary Syndrome
1
Salivary Gland Adenoma, Pleomorphic
1
Interventions
Dexamethasone
21
Calcium Dobesilate
10
Melphalan
9
Bortezomib
8
Cyclophosphamide
7
Lenalidomide
6
pomalidomide
4
miridesap
3
daratumumab
3
venetoclax
2
ixazomib
2
belantamab mafodotin
2
Thalidomide
2
Doxycycline
2
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
2
selinexor
1
pegfilgrastim
1
isatuximab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
carfilzomib
1
birtamimab
1
auricularum
1
Vinorelbine
1
Technetium Tc 99m Pyrophosphate
1
Technetium
1
Tacrolimus
1
Surveys and Questionnaires
1
Pharmaceutical Preparations
1
Lisaftoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Amyloidosis
×
carfilzomib
×
Clear all
NCT02545907
2021-04-15
CATALYST
University College, London
Phase 1/2
Completed
10 enrolled
14 charts